Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -18% Improvement Relative Risk Mortality (b) 1% Mortality (c) -130% Mortality (d) -9% Mortality (e) -90% Mortality (f) -16% Ventilation -29% c19hcq.org Stewart et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 2,399 patients in the USA Higher mortality (p=0.27) and ventilation (p=0.093), not stat. sig. Stewart et al., PLoS ONE, doi:10.1371/journal.pone.0248128 Favors HCQ Favors control
COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
Stewart et al., PLoS ONE, doi:10.1371/journal.pone.0248128
Stewart et al., COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without.., PLoS ONE, doi:10.1371/journal.pone.0248128
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Collection of seven retrospective database analyses in the USA, showing higher mortality with treatment (not statistically significant).
Results contradict strong evidence from the RECOVERY/SOLIDARITY trials, suggesting substantial confounding by indication.
Time based confounding is very likely because HCQ became highly controversial and usage dramatically declined over the time covered, while overall treatment protocols during this period improved dramatically, i.e., more control patients likely come later in the period when treatment protocols were greatly improved.
This study includes anyone PCR+ during or prior to their visit, and anyone with ICD-10 COVID-19 codes which includes asymptomatic PCR+ patients, therefore some patients in the control groups may be asymptomatic with regards to SARS-CoV-2, but in the hospital for another reason.
Authors do not mention the possibility of any of these likely confounding factors. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically; includes PCR+ patients that may be asymptomatic for COVID-19 but in hospital for other reasons.
risk of death, 18.0% higher, RR 1.18, p = 0.27, treatment 90 of 429 (21.0%), control 141 of 737 (19.1%), adjusted per study, VA, HCQ+AZ.
risk of death, 1.0% lower, RR 0.99, p = 0.95, treatment 66 of 578 (11.4%), control 188 of 1,243 (15.1%), adjusted per study, TriNetX, HCQ+AZ.
risk of death, 129.9% higher, RR 2.30, p < 0.001, treatment 32 of 108 (29.6%), control 33 of 256 (12.9%), Synapse, HCQ+AZ.
risk of death, 9.0% higher, RR 1.09, p = 0.65, treatment 212 of 1,157 (18.3%), control 203 of 1,101 (18.4%), NNT 873, adjusted per study, Health Catalyst, HCQ+AZ.
risk of death, 90.0% higher, RR 1.90, p = 0.09, treatment 46 of 208 (22.1%), control 47 of 1,334 (3.5%), adjusted per study, Dascena, HCQ+AZ.
risk of death, 16.0% higher, RR 1.16, p = 0.26, treatment 428 of 1,711 (25.0%), control 123 of 688 (17.9%), adjusted per study, COTA/HMH, HCQ+AZ.
risk of mechanical ventilation, 29.0% higher, RR 1.29, p = 0.09, treatment 48 of 305 (15.7%), control 95 of 1,302 (7.3%), adjusted per study, Aetion, HCQ.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Stewart et al., 17 Mar 2021, retrospective, USA, peer-reviewed, 37 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Stewart M, Rodriguez-Watson C, Albayrak A, Asubonteng J, Belli A, Brown T, et al. (2021) COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLoS ONE 16(3): e0248128. https://doi.org/10.1371/journal.pone.0248128 Editor: Francesco Di Gennaro, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, ITALY Received: December 10, 2020 Accepted: February 20, 2021 Published: March 17, 2021 Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: Health catalyst provided support for this study in the form of salary for AA, EE, AG, and JJ. Gilead Sciences provided support for this study in the form of salary for JA and RM. COTA, Inc provided support for this study in the form of salary for AB, EH, and SG. Sypase provided Mark Stewart1‡, Carla Rodriguez-Watson2‡, Adem Albayrak ID3☯, Julius Asubonteng ID4☯, Andrew Belli5☯, Thomas Brown6☯, Kelly Cho7,8☯, Ritankar Das9☯, Elizabeth Eldridge3☯, Nicolle Gatto10☯, Alice Gelman3☯, Hanna Gerlovin ID7☯, Stuart L. Goldberg11☯, Eric Hansen5☯, Jonathan Hirsch6☯, Yuk-Lam Ho7☯, Andrew Ip ID11☯, Monika Izano ID6☯, Jason Jones3☯, Amy C. Justice12,13☯, Reyna Klesh ID14☯, Seth Kuranz15☯, Carson Lam9☯, Qingqing Mao ID9☯, Samson Mataraso ID9☯, Robertino Mera4☯, Daniel C. Posner7☯, Jeremy A. Rassen ID10☯, Anna Siefkas9☯, Andrew Schrag6☯, Georgia Tourassi16☯, Andrew Weckstein ID10☯, Frank Wolf6☯, Amar Bhat2☯, Susan Winckler2☯, Ellen V. Sigal1,2☯, Jeff Allen1* 1 Friends of Cancer Research, Washington, District of Columbia, United States of America, 2 Reagan-Udall Foundation for the FDA, Washington, District of Columbia, United States of America, 3 Health Catalyst, Salt Lake City, Utah, United States of America, 4 Gilead Science, Inc. Foster City, California, United States of America, 5 COTA, Inc., Boston, Massachusetts, United States of America, 6 Syapse, San Francisco, California, United States of America, 7 Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, United States of America, 8 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 9 Dascena, Oakland, California, United States of America, 10 Aetion, New York, New York, United States of America, 11 Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America, 12 VA Connecticut Healthcare System, West Haven, Connecticut, United States of America, 13 Yale University Schools of Medicine and Public Health, New Haven, Connecticut, United States of America, 14 HealthVerity, Philadelphia, Pennsylvania, United States of America, 15 TriNetX, Cambridge, Massachusetts, United States of America, 16 National Center..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit